Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films
Status:
Suspended
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
While substance use disorders have been found to have relapse rates on part with other
chronic illnesses such as hypertension and asthma long term abstinence remains elusive for
many. The FDA has recently approve a long acting subcutaneous injectable formulation of
buprenorphine. This study aims to determine the feasibility of enrolling and randomizing
patients seeking treatment at an outpatient substance abuse clinic to buprenorphine/naloxone
films which dissolve under the tongue vs. long acting buprenorphine injection with all other
treatment aspects held constant. The study also aims to determine the effectiveness of
monthly injections of Sublocade® compared to daily oral Suboxone® SL therapy in the treatment
of moderate to severe opioid use disorder after twenty-four weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone